Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

10x Genomics, Inc. Director's Dealing 2021

Nov 4, 2021

31830_dirs_2021-11-03_65486582-9faf-419c-a26a-f6a79f4784a6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-11-01

Reporting Person: STUELPNAGEL JOHN R (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-01 Class A Common Stock S 100 $160.33 Disposed 361516 Direct
2021-11-01 Class A Common Stock S 100 $160.75 Disposed 361416 Direct
2021-11-01 Class A Common Stock S 100 $161.52 Disposed 361316 Direct
2021-11-01 Class A Common Stock S 1494 $163.0985 Disposed 359822 Direct
2021-11-01 Class A Common Stock S 2906 $163.8899 Disposed 356916 Direct
2021-11-01 Class A Common Stock S 300 $164.5800 Disposed 356616 Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $162.50 to $163.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $163.50 to $164.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $164.55 to $164.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.